Phototherapy Restores Deficient Type I IFN Production and Enhances Antitumor Responses in Mycosis Fungoides.
Zizi Yu,Pablo Vieyra-Garcia,Theresa Benezeder,Jack D. Crouch,Ira R. Kim,John T. O'Malley,Phillip M. Devlin,Ahmed Gehad,Qian Zhan,Johann E. Gudjonsson,Mrinal K. Sarkar,J. Michelle Kahlenberg,Nega Gerard,Jessica E. Teague,Thomas S. Kupper,Nicole R. Leboeuf,Cecilia Larocca,Marianne Tawa,Bohdan Pomahac,Simon G. Talbot,Dennis P. Orgill,Peter Wolf,Rachael A. Clark
DOI: https://doi.org/10.1016/j.jid.2023.06.212
IF: 7.59
2024-01-01
Journal of Investigative Dermatology
Abstract:Transcriptional profiling demonstrated markedly reduced type I IFN gene expression in untreated mycosis fungoides (MF) skin lesions compared with that in healthy skin. Type I IFN expression in MF correlated with antigen -presenting cell -associated IRF5 before psoralen plus UVA therapy and epithelial ULBP2 after therapy, suggesting an enhancement of epithelial type I IFN. Immunostains confirmed reduced baseline type I IFN production in MF and increased levels after psoralen plus UVA treatment in responding patients. Effective tumor clearance was associated with increased type I IFN expression, enhanced recruitment of CD8 thorn T cells into skin lesions, and expression of genes associated with antigen -specific T -cell activation. IFNk, a keratinocyte-derived inducer of type I IFNs, was increased by psoralen plus UVA therapy and expression correlated with upregulation of other type I IFNs. In vitro, deletion of keratinocyte IFNk decreased baseline and UVA-induced expression of type I IFN and IFN response genes. In summary, we find a baseline deficit in type I IFN production in MF that is restored by psoralen plus UVA therapy and correlates with enhanced antitumor responses. This may explain why MF generally develops in sun -protected skin and suggests that drugs that increase epithelial type I IFNs, including topical MEK and EGFR inhibitors, may be effective therapies for MF.